Summary
The effect of sulphonylurea therapy for 3 weeks on glucose-stimulated insulin secretion and insulin resistance was studied in Type 2 diabetic patients. The fasting plasma insulin and C-peptide concentrations on diet alone were compared with each subject's fasting concentrations on sulphonylurea treatment at a lower fasting plasma glucose and at the original diet-alone glycaemic level obtained by the hyperglycaemic clamp technique. At this isoglycaemic level (mean 11 mmol/l), plasma insulin levels increased from 6.9 mU/l on diet alone to 12.1 mU/l on sulphonylurea treatment (p<0.01). The subjects were also studied by the hyperglycaemic clamp technique at mean glycaemic levels of 13 mmol/l before and after sulphonylurea treatment; the incremental insulin response was similarly enhanced from 7.6±3.5 to 13.7±6.9 mU/l (p<0.02) respectively. Sulphonylureas appear to reduce glycaemia by enhancing B-cell function two-fold. In the patients studied this was from approximately 21% to 37% of a normal response. Insulin resistance assessed by the same hyperglycaemic clamps as endogenous plasma insulin concentrations divided by glucose infusion rates was unchanged by sulphonylurea therapy (mean 4.37 compared to 4.40 mU. 1−1·mg−1·kg·min on diet alone).
Article PDF
Similar content being viewed by others
References
Holman RR, Turner RC (1978) Basal normoglycaemia attained with chlorpropamide in mild diabetes. Metabolism 27: 539–547
Sonksen PH, Lowy C, Perkins JR, West TET (1981) Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetes not controlled on diet alone. Diabetologia 20: 22–30
Elkeles RS, Heding LG, Paisey RB (1982) The long-term effects of chlorpropamide on insulin, C-peptide, and proinsulin secretion. Diabetes Care 4: 427–429
Tsalikian E, Dunphy TW, Bohannon NV, Lorenzi M, Gerich JE, Forsham PH, Kane JP, Karam JH (1977) The effect of chronic oral antidiabetic therapy on insulin and glucagon responses to a meal. Diabetes 26: 314–321
Seltzer HS, Allen EW, Brennan MT (1965) Failure of prolonged sulfonylurea administration to enhance insulinogenic response to glycemic stimulus. Diabetes 14: 392–395
Reaven G, Dray J (1967) Effect of chlorpropamide on serum glucose and insulin concentrations in patients with maturity onset diabetes. Diabetes 16: 487–492
Feldman JM, Lebovitz HE (1971) Endocrine and Metabolic effects of glibenclamide. Evidence for an extra pancreatic mechanism of action. Diabetes 20: 745–755
Duckworth WC, Solomon SS, Kitabchi CJ (1972) Effect of chronic sulphonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab 35: 585–591
Barnes AJ, Crowley MF, Garbien KJT, Bloom A (1974) Effect of short and long-term chlorpropamide treatment on insulin release and blood glucose. Lancet 1: 69–72
Shenfield GM, Logan A, Stirling D, Baird J (1977) Plasma insulin and glucose lipids in maturity onset diabetes treated with chlorpropamide. Diabetologia 13: 367–371
Sartor G, Scherten B, Melander A (1978) Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients. Acta Med Scand 203: 211–214
Pfeifer MA, Jeffrey B, Halter B, Graf R, Porter D (1980) Potentiation of insulin secretion to nonglucose stimuli in normal man by tolbutamide. Diabetes 29: 335–340
DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214–223
Albano JDM, Ekins RP, Maritz G, Turner RC (1972) A sensitive, precise, radioimmunoassay of serum insulin relying on charcoal separation of bound and free hormone moieties. Acta Endocrinol 70: 487–509
Holman RR, Turner RC (1977) Diabetes: the quest for basal normoglycaemia. Lancet 1: 469–474
Holman RR, Turner RC (1979) Maintenance of basal plasma glucose and insulin concentration in maturity-onset diabetes. Diabetes 28: 227–230
Turner RC, Holman RR (1976) Insulin rather than glucose homeostasis in the pathophysiology of diabetes. Lancet 1: 1272–1274
Turner RC, Holman RR, Matthews DR, Peto J (1982) Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes. Lancet 1: 596–598
Faber OK, Kehlet H, Madsbad S, Binder C (1978) Kinetics of human C-peptide in man. Diabetes 27: 207–209
Turner RC, Grayburn JA, Newman GB, Nabarro JDN (1971) Measurement of the insulin delivery rate in man. J Clin Endocrinol Metab 33: 279–286
Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM (1984) The acute and chronic effects of sulfonylurea therapy in Type II diabetic subjects. Diabetes 33: 346–354
Beck-Nielsen H, Lindskov HO, Richelsen B, Faber O, Binder C (1983) Mechanism of action of glibenclamide in Type 2 (non-insulin-dependent) diabetes during long term treatment. Diabetologia 23: 153 (Abstract)
Judzewitsch RG, Pfeifer MA, Best JD, Beard JC, Halter JB, Porte DJ (1982) Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose. J Clin Endocrin Metab 55: 321–332
Pfeifer MA, Halter JB, Porte D (1981) Insulin secretion in diabetes mellitus. Am J Med 70: 579–588
Pfeifer MA, Halter JB, Judzewitsch RG, Beard JC, Best JD, Ward WK, Porte D (1984) Acute and chronic effects of sulphonylurea drags on pancreatic islet cell function in man. Diabetes Care 7: 1; 25–34
Hosker JP, Burnett MA, Davies EG, Matthews DR, Rudenski A, Turner RC (1984) Loss of normal sigmoid, beta-cell dose-response curve to glucose in non-insulin-dependent diabetes. Diabetologia 27: 289 (Abstract)
Daniel PM, Love ER, Pratt OE (1975) Insulin stimulated entry of glucose into muscle in vivo as a major factor in the regulation of blood glucose. J Physiol 247: 273–288
Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM (1976) Receptor and postreceptor defects contribute to the insulin resistance in non-insulin-dependent diabetes mellitus. J Clin Invest 68: 957–969
Olefsky JM, Reaven GM (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetics patients. Am J Med 60: 89–95
Feinglos MN, Lebovitz HE (1978) Sulfonylureas increase the number of insulin receptors. Nature 276: 184–185
Maloof BL, Lockwood DH (1981) In vitro effects of a sulfonylurea on insulin action in adipocytes. J Clin Invest 68: 85–90
Salhanick AI, Konnowitz P, Amatruda JM (1983) Potentiation of insulin action by a sulfonylurea in primary cultures of hepatocytes from normal and diabetic rats. Diabetes 32: 206–212
Putnam WS, Anderson DK, Jones RS, Lebovitz HE (1981) Selective potentiation of insulin-mediated glucose disposal in normal dogs by the sulfonylurea glipizide. J Clin Invest 67: 1016–1023
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hosker, J.P., Burnett, M.A., Davies, E.G. et al. Sulphonylurea therapy doubles B-cell response to glucose in Type 2 diabetic patients. Diabetologia 28, 809–814 (1985). https://doi.org/10.1007/BF00291069
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00291069